Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Amsterdam  >  Probiodrug    PBD   DE0007921835

PROBIODRUG (PBD)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Euronext Amsterdam
06/12/2018 06/13/2018 06/14/2018 06/15/2018 06/18/2018 Date
4.61(c) 4.62(c) 4.65(c) 4.58(c) 4.55 Last
52 289 18 005 11 956 42 935 7 405 Volume
-3.15% +0.22% +0.65% -1.51% -0.66% Change
More quotes
Financials (EUR)
Sales 2018 -
EBIT 2018 -7,80 M
Net income 2018 -7,80 M
Finance 2018 2,80 M
Yield 2018 -
Sales 2019 -
EBIT 2019 -11,9 M
Net income 2019 -12,9 M
Debt 2019 4,83 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0
EV / Sales2019 0
Capitalization 37,6 M
More Financials
Company
Probiodrug AG is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease.Its product pipeline includes PQ912, PBD-C06, and PQ1565.The company was founded by Hans-Ulrich Demuth and Konrad Glund on July 25, 1997 and... 
Sector
Biotechnology & Medical Research
Calendar
06/21 | 11:00amShareholder meeting
More about the company
Latest news on PROBIODRUG
05/23PROBIODRUG AG : Notification and public disclosure of transactions by persons
EQ
05/23PROBIODRUG AG : Notification and public disclosure of transactions by persons
EQ
05/15PROBIODRUG AG : reports First Quarter 2018 Business Update
AQ
05/15PROBIODRUG : Crossing thresholds
CO
05/15PROBIODRUG : 1st quarter results
CO
05/09PROBIODRUG AG : to hold its Ordinary General Meeting of Shareholders on 21 June..
AQ
05/09PROBIODRUG : Mixed general shareholder meeting
CO
05/08PROBIODRUG : positioning its pGlu-Abeta Antibody in the field of Abeta antibodie..
AQ
05/08PROBIODRUG AG : to Publish its First Quarter 2018 Business Update on 15 May 201..
AQ
04/24PROBIODRUG : Appoints Dr. Ulrich Dauer as Chief Executive Officer
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/01Lilly, Incyte Get FDA OK for Lower-Dose Rheumatoid Arthritis Drug
DJ
05/30Gap in regulating biotech drug copies prompts WHO to step in
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
04/13$PBD AG Probiodrug - Emerging details of PQ912 late-stage development: The h.. 
04/10German biotech Probiodrug is hoping its lead Alzheimer’s candidate can make a..
1
04/10Probiodrug (PBD-NA): Lifting the veil on Phase IIb design
2
03/27Probiodrug AG: Preliminary announcement of the publication of financial repor.. 
03/27Probiodrug AG: Preliminary announcement of the publication of financial repor.. 
More tweets
Qtime:25
News from SeekingAlpha
2017Probiodrug AG 2017 Q2 - Results - Earnings Call Slides 
2017SNIPPET ROUNDUP : Novartis Enters Advair Generic Race, Biogen Dealt CFO Blow 
2017Biomarin's Rare Disease Approval And Probiodrug's Alzheimer's Play 
2015BP Energy Outlook 2035 Shows More Work Needs To Be Done On Carbon Reduction 
Chart PROBIODRUG
Duration : Period :
Probiodrug Technical Analysis Chart | PBD | DE0007921835 | 4-Traders
Technical analysis trends PROBIODRUG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 30,0 €
Spread / Average Target 555%
EPS Revisions
Managers
NameTitle
Ulrich Dauer Chief Executive Officer
Erich Maximilian Platzer Chairman-Supervisory Board
Inge Lues Chief Development Officer
Jörg Neermann Member-Supervisory Board
Dinnies Johannes von der Osten Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
PROBIODRUG-56.79%44
CELLTRION, INC.--.--%33 987
IQVIA HOLDINGS INC5.50%21 394
LONZA GROUP3.38%20 341
INCYTE CORPORATION-21.91%15 677
ALNYLAM PHARMACEUTICALS, INC.-15.15%10 836